Dr. Kamala Ley-Thriemer
Senior research fellow
PhD, University Antwerp, Belgium, 2013; Master of Public Health, University Liverpool, UK, 2011; Medical degree, Medical University Vienna, Austria, 2005
Approved level of HDR supervision at Charles Darwin University:
Primary supervisor for PhD
Kamala is a CSL Centenary Fellow at Menzies School of Health Research. Her main research interest is to develop and optimise treatment programs against vivax malaria in south-east Asia and the Horn of Africa. Her research program spans from clinical trials and epidemiological studies to policy and implementation research. She is also a lecturer at Charles Darwin University and coordinates the Vivax Working Group (VxWG) of the Asia Pacific Malaria Elimination Network (APMEN).
Kamala graduated from the Medical University Vienna (MUV), Austria in 2005 where she first began researching antimalarial drug resistance in Thailand and Bangladesh. Kamala graduated with a Master of Public Health from the University of Liverpool in 2011 and received her PhD degree from the University Antwerp, Belgium.
She has lived and worked in the field in both Asia and throughout Africa for more than eight years. She started her research career at the International Center for Diarrheal Diseases (icddr,b) in Bangladesh focusing on clinical and epidemiological studies to define the burden of falciparum malaria. She subsequently worked with the International Vaccine Institute (IVI) based in Tanzania and Kenya and then at the Institute for Tropical Medicine (ITM), Belgium where her research interests included malaria, typhoid fever and cholera.
Kamala has received more than $3.5 million competitive research grants in the last year.
- Optimizing the radical cure of P.vivax malaria (OPRA)
- ACROSS Study: Populations at risk of malaria and drug induced haemolysis
- PRIMA clinical trial: Universal Radical Cure of P. vivax malaria
- SIRIN clinical trial: Radical cure of P. vivax malaria in Nepal
- IMPROV Study: Short-course treatment regimen for radical cure of P. vivax malaria
- Asia Pacific Malaria elimination network (APMEN).
- Taylor, W.R.J.*, Thriemer, K.*, von Seidlein, L., Yuentrakul, P., Assawariyathipat, T., Assefa, A., et al. (2019). Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet, 394 (10202), 929-938. doi: 10.1016/S0140-6736(19)31285-1.
- Commons, R.J., Simpson, K.A., Thriemer ,K., Hossain, M.S., Douglas, N.M., Humphreys, G.S., et al. (2019) Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis. Lancet Infect Dis,19(1), 91-101. doi: 10.1016/S1473-3099(18)30596-6.
- Thriemer, K., Bobogare, A., Ley, B., Gudo, C.S., Alam, M.S., Anstey, N.M., et al (2018). Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group. Malar J, 17(1):241. doi: 10.1186/s12936-018-2380-8.
- Ley, B., Thriemer, K., Jaswal, J., Poirot, E., Alam, M.S., Phru, C.S., et al. (2017) Barriers to routine G6PD testing prior to treatment with primaquine. Malar J, 16(1):329. doi: 10.1186/s12936-017-1981-y.
- Htun, M. W., Mon, N.C.N., Aye, K.M., Hlaing, C.M., Kyaw, M.P., Handayuni, I. et al. (2017). Chloroquine efficacy for Plasmodium vivax in Myanmar in populations with high genetic diversity and moderate parasite gene flow. Malar J, 16(1):281. doi: 10.1186/s12936-017-1912-y.
- Wangchuk, S., Drukpa, T., Penjor, K., Peldon, T., Dorjey, Y., Dorji, K., Chhetri, V., Trimarsanto, H., To. S., Murphy, A., von Seidlein, L., Price, R.N., Thriemer, K.*, Auburn, S.* (2016). Where chloroquine still works: the genetic make-up and susceptibility of Plasmodium vivax to chloroquine plus primaquine in Bhutan. Malaria Journal,15(1), 277. doi: 10.1186/s12936-016-1320-8.
- Abreha, T.*, Hwang, J.*, Thriemer, K.* , Tadesse, Y., Girma, S., Melaku, Z., et al. (2018) Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial. PLOS Medicine 15(10): e1002677. https://doi.org/10.1371/journal.pmed.1002677
- Thriemer, K., Ley, B., Bobogare, A., Dysoley, L., Alam, M.S., Ayodhia, P., et al. (2017). Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group. Malar J, 16(1), 141. doi: 10.1186/s12936-017-1784-1
- PREGACT Study Group, Pekyi, D., Ampromfi, A.A., Tinto, H., Traoré-Coulibaly, M., Tahita, M.C., et al. (2016). Four Artemisinin-Based Treatments in African Pregnant Women with Malaria. New England Journal of Medicine, 374(10), 913-27. doi: 10.1056/NEJMoa1508606.
- Thriemer, K., Hong, N.V., Rosanas-Urgell, A., Phuc, B.Q., Ha, D.M., Pockele, E., et al. (2014). Delayed parasite clearance after treatment with dihydroartemisinin-piperaquine in Plasmodium falciparum malaria patients in Central Vietnam. Antimicrobial Agents and Chemotherapy, 58(12), 7049-55. pii: AAC.02746-14.
* shared authorship
In this edition, we are proud to present a snapshot of the announcements, awards and events that have occurred over the past few months.
Menzies School of Health (Menzies) researcher Dr Kamala Thriemer has been awarded a prestigious $1.25 million CSL Centenary Fellowship to develop and optimise treatment programs against vivax malaria in SE Asia and the Horn of Africa.
Two Australian scientists have each been awarded AUD$1.25 million CSL Centenary Fellowships over five years to improve treatments for two of the world’s biggest health challenges: malaria and cancer.
A new research study has shown that a seven-day treatment with a high dose of an anti-malaria drug can be tolerated by patients
A large clinical trial in Africa and Asia has shown that a 7 day course of high dose primaquine, a drug used to treat P. vivax malaria, is well tolerated.
MESA Correspondents bring you cutting-edge coverage from the 7th International Conference on Plasmodium vivax Research (ICPVR 2019).
Wrapping up the 7th International Conference on Plasmodium vivax Research, day three focused on the topics of P. vivax drugs and approaches for P. vivax elimination.
The largest grant, of $257,767, goes to the Menzies School of Health Research for a project with collaborators in Bangladesh, Indonesia and the Netherlands.
Among the other projects funded are the Menzies School of Health Research partnering with Bangladesh, Indonesia and Nepal to develop malaria treatments.
A study led by the Menzies School of Health Research recommends a two-stage treatment for the notoriously difficult-to-cure Plasmodium vivax malaria
A study into the treatment of the difficult-to-cure Plasmodium vivax malaria in Ethiopia.